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Abstract
Preimplantation genetic diagnosis (PGD) was originally developed to diagnose embryo-related genetic abnormalities for couples
who present a high risk of a specific inherited disorder. Because this technology involves embryo selection, the medical,
bioethical, and legal implications of the technique have been debated, particularly when it is used to select features that are not
related to serious diseases. Although several initiatives have attempted to achieve regulatory harmonization, the diversity of
healthcare services available and the presence of cultural differences have hampered attempts to achieve this goal. Thus, in
different countries, the provision of PGD and regulatory frameworks reflect the perceptions of scientific groups, legislators, and
society regarding this technology. In Brazil, several texts have been analyzed by the National Congress to regulate the use of
assisted reproduction technologies. Legislative debates, however, are not conclusive, and limited information has been published
on how PGD is specifically regulated. The country requires the development of new regulatory standards to ensure adequate
access to this technology and to guarantee its safe practice. This study examined official documents published on PGD regulation
in Brazil and demonstrated how little direct oversight of PGD currently exists. It provides relevant information to encourage
reflection on a particular regulation model in a Brazilian context, and should serve as part of the basis to enable further reform of
the clinical practice of PGD in the country.
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Introduction
Preimplantation genetic diagnosis (PGD) involves the
genetic testing of embryos obtained through in vitro fertili-
zation (IVF). It was originally developed as an alternative
approach to prenatal diagnosis for couples who present a
high risk of transmitting a genetic defect (1). The technique
involves conducting genetic analyses on embryonic
cells and then transferring the unaffected embryos into the
uterus. Because this form of reproductive technology
involves embryo selection, the medical, bioethical, and
legal implications of the technique have been debated
since its first application in 1989, particularly when it is used
to select features that are not related to serious diseases
(2-4). PGD has become a routine diagnostic procedure in
the area of assisted reproduction, and countries have
adopted very different legal approaches to its regulation,
to the jurisdiction of authority, and to the nature of enforce-
ment (1).
A milestone in international legislation occurred with the
publication of the Warnock Report in the United Kingdom
in 1984, which presents recommendations that are widely
used as an international reference for the regulation of
reproductive technologies (5). However, concerning PGD,
complex issues related to ethics and equitable access to
embryonic genetic testing have grown even more compli-
cated and controversial in legislative debates. Although
several initiatives have attempted to achieve regulatory
harmonization across Europe and on other continents, a
diversity of healthcare systems and the presence of cultur-
al differences have hampered attempts to achieve this
goal (2). Some initiatives of international organizations are
relevant in this regard, such as the guidelines published
by the European Society of Human Reproduction and
Embryology (ESHRE). The ESHRE PGD Consortium not
only reflects on the current use of PGD but also offers
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consensus-based specific guidance regarding how best to
practice clinical PGD based on clinical experience and
data, both published and unpublished. The Consortium
hopes that minimum standards of quality and safety might
be achieved across all services actively providing clinical
PGD, and recognizes that, owing to variations in local
or national regulations and specific laboratory practices,
there will remain differences in the ways in which PGD is
practiced. However, this does not preclude a series of
consensus opinions on best practices based on the
available evidence (6,7).
Political scientists, doctors, and bioethics experts
have discussed the need for governments to improve the
regulation of research into and clinical use of assisted
reproduction technologies (ART) (5,8-11). Some argue for
the adoption of new legislation to allow scientists to realize
the potential benefits of reproductive technologies to human
health. Others see legislation as necessary to prevent
scientific exploration into areas that are ethically unaccept-
able. Some, of course, question the need for any govern-
ment involvement. Knoppers et al. (2) highlighted the
difficulties and limitations of establishing specific uses for
PGD. For other political scientists, the practice of PGD
depends not only on regulation itself but also on the
structure of a country’s healthcare system and social policy,
ethical and scientific guidelines for selecting indications,
and mechanisms and criteria for health insurance reim-
bursement (11,12).
Thus, in each country, PGD is used with a specific
approach that should reflect the views held by scientific
groups, professional societies, legislators, and the society
itself on the appropriate use of this technology. Although
countries such as Austria and Germany have banned the
use of PGD, others, such as Japan, Israel, Canada, and the
United Kingdom, are discussing new uses for PGD and
regulation strategies to maintain the method’s reliability by
defining standards and responsibilities for professionals
performing PGD and by protecting the rights of those
concerned. In France and certain regions of Australia, India,
and the Netherlands, regulations define the circumstances
under which PGD is permissible. In other countries, such as
the United States, there are no direct regulations for the
technique, and, instead, professional guidelines for practic-
ing service providers are consulted (2).
In Brazil, limited information has been published on PGD
regulation, and no official organization regulates or system-
atically collects data on this practice. Hence, very little is
known about the practice of PGD in Brazil. Although there
have been some achievements in recent decades in the field
of reproductive rights, issues such as those related to ART
have been addressed timidly, especially in the context
of hereditary genetic diseases. For regulation, the country
relies on the use of various documents that are integral to
the national agenda on reproductive health and human
rights (13) but which are only loosely related to PGD. Since
the late 1990s, several texts have been analyzed by the
National Congress to regulate the use of ART in the country.
However, legislative debates remain inconclusive (14). Ad-
vancements of this technology in Brazil have increased
State commitments to society, which involve the adoption of
new regulatory standards and more ambitious policy goals
that ensure access to this technology while guaranteeing its
safe practice. Hence, an analysis of official documentation
on PGD regulation in Brazil was conducted to demonstrate
how loosely this reproductive technology is regulated in this
country. This study provided relevant information related
to the public policy and legislative framework of PGD to
encourage the introduction of a specific regulation model
that promotes the adoption of PGD best practices in Brazil.
Data collection
Data for the analysis were drawn from official documents
published by major regulatory organizations in Brazil that
have worked in this field, from 1992 through August 2013.
The period of study began in 1992 because the first official
document on ART regulation in Brazil was published in that
year by the Federal Council of Medicine [Conselho Federal
de Medicina (CFM)]. Owing to the absence of specific
regulation on PGD, the search for data on ART regulation
in Brazil was extended, so that documentation that may
contribute to PGD regulation was collected for analysis. The
terms ‘‘assisted reproduction’’ (‘‘reproduc¸a˜o assistida’’) or
‘‘human reproduction’’ (‘‘reproduc¸a˜o humana’’) were used
as search terms. Following criteria for authenticity and
reliability, materials were surveyed in the National Public
Archives in their printed (official publications) and digital
(online) forms from the following Brazilian institutions: the
National Press (http://www.in.gov.br), the House of
Representatives (http://www.camara.leg.br), the Senate
(http://www.senado.gov.br), the Ministry of Health (http://
portal.saude.gov.br), and the Federal Council of Medicine
(http://www.portal.cfm.org.br). Twenty-two documents
formed the final corpus of analysis as follows: one common
law (Law 11.105/2005), eight bills (Bill 3638/1993, Bill 2855/
1997, Bill 1135/2003, Bill 2061/2003, Bill 1184/2003 toge-
ther with its 12 attachments, Bill 5624/2005, Bill 5730/2009,
and Bill 4892/2012), one piece of Secretary of Health
Care [Secretaria de Assisteˆncia a` Sau´de (SAS)] legislation
(Ordinance 388/2005 SAS), four pieces of the Minister’s
Office [Gabinete do Ministro (GM)] legislation (Ordinance
426/2005 GM, Ordinance 1.187/2005 GM, Ordinance 2.048/
2009 GM, and Ordinance 3.149/2012 GM), four pieces of
Directors’ Collegiate Resolution [Resoluc¸a˜o da Diretoria
Colegiada (RDC)] legislation (RDC 33/2006, RDC 29/2008,
RDC 9/2011, and RDC 23/2011), and four CFMResolutions
(CFM 1358/1992, CFM 1931/2009, CFM 1957/2010, and
CFM 2013/2013).
The selected content was organized and evaluated
according to the content analysis approach presented by
Bardin (15). For the initial stage of content analysis, the texts
were carefully reviewed, and documents related to the fields
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of interest were selected. The material was subsequently
categorized according to relevance and then grouped into
two categories of ART access regulation in the context of
hereditary genetic diseases, as provided in 1) public policies
and 2) legislative frameworks.
Results
Regulation of access to ART as provided in Brazilian
public policies
Issues related to reproductive technology access form
an integral component of the public health agenda in Brazil
in the area of reproductive rights, which is related to human
rights and the right to health (13). Hence, to understand
the current debates surrounding public policies in Brazil in
this context, it is necessary to provide a brief analysis of
reproductive rights in this country.
In Brazil, the principles of universality, equality, and
equity are recognized as guiding principles that direct health
services (16). Concerning the right to procreation, state-
ments contend (Article 226, 7th paragraph of CF/88, and
Organic Health Law 8.080/90) that family planning is both
the citizen’s right and a State responsibility, and that the
Unified Health System [SistemaUnificado de Sau´de (SUS)],
on all levels, is obliged to ensure ‘‘assistance with concep-
tion and contraception’’ (Law 9.263/96) (17). However, the
currently adopted approach that combines conception with
reproductive health was only introduced in the country in
1984 through the Program for Integral Attention to Women’s
Health (Programa de Assisteˆncia Integral a` Sau´de da
Mulher) (18), which was a milestone toward the goal of
making the issue of reproductive health a health policy
concern rather than one of population control.
During that same period, the issue of international
reproductive rights was highlighted in the International
Conference on Population and Development (CIPD; Cairo,
1994) and the IV World Conference on Women (Beijing,
1995), in which Brazil was an important participant. The
establishment of the CIPD generated a movement away
from the traditional focus on population growth and toward a
discussion on strategies for promoting dignified lifestyles in
various areas, including the realm of sexual and reproduc-
tive rights (13,18).
In this context, several legal approaches were created in
Brazil from the 1990s, to legitimize the notion of sexual and
reproductive rights. The Family Planning Law (Law 9.263/
96), for instance, introduced normative views on reproduc-
tive rights to Brazil, related to such issues as contraception
and conception assistance. The law defines family planning
as the ‘‘set of actions regulating fertility and ensuring equal
rights under the constitution for a limitation or increase in
offspring by woman, man or couple’’ (17). However, despite
the level of freedom ensured by this legislation, universal
access has not been accomplished in reality, and, while
public policy actions on ART have been developed (Table 1),
they have also failed to ensure this right.
In 2004, the Health Ministry launched the National Policy
on Sexual and Reproductive Rights (19) in response to
social demand, international legal frameworks, and govern-
ment precepts of the SUS. This approach culminated in the
drafting of the National Policy for Integral Attention in Human
Reproduction (Ordinance 426/2005 GM), which was recog-
nized as a landmark public policy on conceptive care. In July
2005, SAS Decree 388/2005, which regulates the previous
Table 1. Public policies aimed at assisted reproduction techniques (ART) with respect to hereditary genetic diseases in Brazil.
Title/Date Comments
Nat. Policy Sexual and Reproductive Rights
(Polı´tica Nac. Direitos Sexuais e
Reprodutivos – MS; 2004)
Establishes guidelines to ensure sexual and reproductive rights, including attention
to assisted reproduction in SUS.
Nat. Policy for Integral Attention in Human
Reproduction (Polı´tica Nac. Atenc¸a˜o Integral
em Reproduc¸a˜o Humana Assistida –
Ordinance 426/2005 GM)
Intended for infertile couples and those with infectious-contagious and genetic diseases,
the establishment of a specific policy for assisted reproduction care at various levels of
healthcare through SUS was a milestone in government policy concerning conception.
Ordinance 388/2005 SAS Gives the necessary support to organize and implement the State, City, and Federal
District networks in Assisted Human Reproduction care.
Ordinance 1.187/2005 GM Suspends previous ordinances for the analysis of the financial impacts and assessment
of the Tripartite Inter-managers Committee.
Ordinance 2.048/2009 GM Approves a new regulation in SUS for ART and revokes ordinance 426/2005 GM
before its implementation under the justification of the need for an impact and financial
resources assessment. Thus, there is no universal access in Brazil to the new
reproductive technologies in SUS, violating the rights legitimized by the National Law.
GM: Gabinete do Ministro (Minister’s Office); MS: Ministe´rio da Sau´de (Health Ministry); SAS: Secretaria de Assisteˆncia a` Sau´de
(Secretary of Health Care); SUS: Sistema U´nico de Sau´de (Unified Health System).
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ordinance and provides organizational and logistical support
to state, city, and Federal District networks, was issued.
However, the decree was later considered ineffectual and
was revoked by Ordinance 1.187/2005 GM.
In 2009, Ordinance 2.048/2009GM (Chapter II, Section
II, Subsection IV, Articles 305-310) was issued, revoking
Ordinance 426/2005 GM and replacing the National Policy
for Integral Attention in Human Reproduction in the govern-
ment agenda. This ordinance introduced a new approach
to ART regulation in the SUS that was targeted to infer-
tile couples and those who might benefit from vertical
or horizontal transmission disease control, including the
control of infectious-contagious and hereditary genetic
diseases.
Also in 2009, several advances were made in the area
of clinical genetics with the institution of the SUS National
Policy for Integral Attention in Clinical Genetics (Ordinance
81/2009 SAS) (20); however, this policy has not yet been
implemented. The ordinance highlighted the importance
of genetic counseling as the major healthcare service of
clinical genetics and stressed that congenital abnormalities
and genetically determined diseases are more prevalent
in developing countries, possibly as a result of a lack of
proper preventive care and therapeutic services.
Despite the indisputable progress of these public policies
and stated goals, these projects have faced numerous
challenges in their implementation. These challenges are
largely attributable to resource shortages, limited cover-
age, a lack of qualifications, unequal access to reproduc-
tive health services, limited awareness, noncompliance with
laws, and difficulty integratingmanagement structures across
several public administration spheres of the decentralized
health system (21). Such challenges are commonly found
in other developing countries, and it is evident that, in the
face of numerous obstacles and demands, the government
actions to secure these rights in Brazil have not been
forthcoming until recently.
Although the National Policy for Integral Attention
in Human Reproduction regulates ART in the SUS, this
legislation does not fully ensure access rights. According to
recent research conducted by Makuch et al. (22,23), only
five services provided through the public system offer ART,
and those services are provided under limited circum-
stances and with no reference to PGD practice. The study
demonstrated that a lack of ART at the state and city levels
is typically attributable to a ‘‘lack of government will to imple-
ment it’’, followed by a ‘‘shortage of human and financial
resources’’ (22). This lack of government commitment
results in unequal access to this service among low-income
couples (24), and the exclusion of this group from repro-
ductive rights provided by law.
Regulation of ART within the Brazilian legislative
frameworks
To understand the nature of PGD regulation in Brazil,
one must review the progression of ART regulation that
began in 1992, almost 10 years after the first IVF in the
country. Regulation was first introduced with the adoption of
Resolution CFM 1358/1992, issued by the CFM, the most
prominent institution for the control of medical practices
in the country. A hybrid collection of professional and
bioethical standards, the resolution establishes guidelines
on the use of ART and has remained, until recently, the only
directive on professional services in this field. From the late
1990s, reproductive rights were introduced as part of the
country’s health policy agenda, and several bills and other
legislative proposals have been analyzed by the National
Congress to regulate the practice of ART. Legislative
debates, however, have not been conclusive (Table 2) (14).
The first bill (Bill 3638/1993) and the other subsequent
bills (Bill 2855/1997, Bill 1135/2003, and Bill 2061/2003)
in this field make little mention of embryonic diagnostic
techniques and merely reproduce the CFM resolution. In
2003, Bill 1184/2003 was approved by all Committees of
the Senate and was presented to the Federal Chamber,
suggesting the imminent adoption of an ART law into
Brazilian legislation. However, the bill continues to await
assessment by the Committee on the Constitution, Justice,
and Citizenship. The spectrum of problems addressed in
the first eight chapters of this bill was very broad, regulating,
among other things, the use of ART for the prevention of
hereditary genetic diseases. Changes made to the bill text
throughout its evaluation led experts to consider the bill
exceedingly controlling. There are 12 attachments to the
bill (Bill 120/2003, Bill 4686/2004, Bill 1135/2003, Bill 2061/
2003, Bill 4889/2005, Bill 4664/2001, Bill 6296/2002, Bill
5624/2005, Bill 3067/2008, Bill 7701/2010, Bill 3977/2012,
and Bill 4892/2012), but none specifically discuss PGD.
In 2005, the drafting of the National Policy for Integral
Attention in Human Reproduction (Ordinance 426/2005
GM) by theMinistry of Health highlighted Bill 5624/2005 that
was instated, which addresses access to ART technology
in the SUS and establishes a program that provides ART
access to individuals with infertility or genetic and infectious-
contagious diseases. Regarding access to ART within the
private healthcare system, Bill 5730/2009 proposes that
ART be included as a private healthcare procedure that is
covered by insurance, but is still awaiting approval.
In an effort to ensure ART access, Federal Law 11.935
(20), in force since 2009, obliged private healthcare
insurance companies to ensure ART coverage based
on the Family Planning Law. However, subsequently,
the National Agency for Supplementary Health (Ageˆncia
Nacional de Sau´de Complementar) through the Normative
Resolution [Resoluc¸a˜o Normativa (RN)] 211/2010 (25)
excluded ART from the list of procedures covered by
healthcare insurance. Thus far, there is no coverage for ART
by health insurance companies in Brazil, which is included in
PGD. Nevertheless, discussions surrounding the legitimacy
of this coverage, especially with respect to PGD for medical
conditions, spurred new lawsuits based on pre-established
reproductive rights.
28 B.B. Damian et al.
Braz J Med Biol Res 48(1) 2015 www.bjournal.com.br
Concerning control over ART clinics in the country,
progress was achieved in 2005 with the implementation of
the Law of Biosafety (Law 11.105/2005), which provides
guidelines on the use of embryonic stem cells produced via
IVF for research and therapy purposes in Brazil. In 2006,
the National Health Surveillance Agency (Ageˆncia Nacional
de Vigilaˆncia Sanita´ria) approved the technical regulation
of Banks of Germ Cells and Tissues [Banco de Celulas e
Tecidos Germinativos (BCTG)] with RDC 33/2006 and RDC
29/2008. The latter resulted in the creation of the National
System for the Production of Embryos (Sistema Nacional de
Produc¸a˜o de Embrio˜es or SisEmbrio), which aims to create
a database of the number of embryos stored in the BCTG.
Subsequently, with the induction of RDC 9/2011 and
RDC 23/2011, this body was assigned the responsibility to
regulate this operation. These resolutions do not explore
the regulation of ART clinics for PGD and do not provide
guidelines for best practices of this technique. Thus, they
perpetuate autonomy for services and professionals in
Brazil, whichmay be detrimental to the safety and efficacy of
PGD in the country.
Considering that there was a lack of regulation of many
aspects of ART, the CFM addressed ART nearly two de-
cades after Resolution CFM 1358/1992. The CFM proposed
a new Code of Medical Ethics (CFM 1931/2009), in which
Articles 14, 15, and 16 discuss human reproduction. With
respect to the use of embryonic cells, Article 15, Paragraph
2 prohibits physicians from creating genetically modified
humans or embryos for research purposes, sex selec-
tion, eugenics, or the generation of hybrids or chimeras.
Table 2. Major legislation and other proposals aimed at assisted reproduction techniques (ART) in the context of hereditary genetic
diseases in Brazil.
Title/Date Comments
CFM 1358/1992 Adopts ethical standards for the use of ART, such as deontological devices, to be followed by doctors.
Bill 3638/1993 First bill of the legislature on the theme. The bill was considered a transposition of CFM 1358/1992, mistakenly
maintaining the perception that the discussion was about a purely technical issue for reproductive medicine,
thereby resulting in an indifferent legislative debate for a decade despite the other bills that followed during that
period.
Bill 1184/2003 Approved by the Federal Senate, this bill provides guidelines for the use of ART in cases of infertility and the
prevention of genetic diseases linked to sex or in cases of medical indications, considering other treatment
options available, such as hereditary genetic diseases. Currently, there are 12 appendices in the House of
Representatives, indicating that the legislative process will be jointly held and awaits approval.
Bill 5624/2005 Creates the Program for Assisted Reproduction in the SUS and provides other measures. Its goal, among
others, is to offer ART for people with genetic diseases. It is appended to Bill 5624/2005.
RDC 33/2006 and
RDC 29/2008
Establishes the technical regulation for the operation of the Bank of GermCells and the sending of information on
human embryos created by IVF (SisEmbrio) to monitor this activity and produce compilation of national data.
Bill 5730/2009 Amendment to Law 9656/1998, which ‘‘refers to private healthcare insurance’’ and determines the inclusion of
assisted reproduction among the services offered by health insurances. Appended to Bill 4076/2001.
CFM 1931/2009 Establishes good medical practice with respect to the use of ART, and establishes guidelines for the use of
embryonic cells and gene therapies (articles 14, 15 and 16).
RDC 9/2011 and
RDC 23/2011
Refers to the operation of Cell Technology Centers for the purpose of clinical research and therapy and
provides other measures.
CFM 1957/2010 Repeals the old resolution CFM 1358/1992 and refers to ethical guidelines for professionals and services of
ART. Refers to embryonic genetic testing for selecting sex with medical indications and in the prevention of
hereditary genetic disorders.
Bill 4892/2012 Establishes the Statute for Assisted Reproduction to regulate the implementation and use of ART and its
effects in the context of social civil relationships. Appended to Bill 1184/2003.
CFM 2013/2013 Confirms the use of PGD to avoid diseases related to the sex of the child and refers to its use for the diagnosis
of disease-causing genetic alterations and for the selection of embryos by histocompatibility.
SUS: Sistema U´nico de Sau´de (Unified Health System); IVF: in vitro fertilization; CFM: Conselho Federal de Medicina (Federal Council
of Medicine); PGD: preimplantation genetic diagnosis. RDC: Resoluc¸a˜o da Diretoria Colegiada (Directors’ Collegiate Resolution).
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Paragraph 3 reinforces the importance of clarification and
agreement between involved parties prior to procedure
execution. Article 16 notes that, regarding the ‘‘application of
knowledge generated from new technologies, considering
its impact both in the present and on future generations, the
physician must ensure that individuals are not discriminated
against based on genetic inheritance, thus protecting their
dignity, identity and integrity’’.
In 2010, in response to the complicated nature of these
issues, the progression of technical scientific advances,
and ethical dilemmas, the CFM conducted a review of
Resolution CFM 1358/1992. In doing so, the CFM con-
vened representatives of the Brazilian Society of Human
Reproduction and Brazilian Federation of Gynecology and
Obstetrics Societies to create Resolution CFM 1957/2010,
providing an important space for debate on this issue in
Brazil. The resolution provides new ethical directives on
ART professional services and revokes the now redundant
Resolution CFM 1358/1992.
In 2010, the first direct reference to PGD was made,
establishing guidelines on sex selection, genetic testing for
medical conditions, and the prevention of hereditary genetic
diseases. General reference was made to controversial
issues such as those related to safety, efficacy, and legal
ethical aspects of PGD. In this way, clinical and professional
practitioners in Brazil were able to maintain their autonomy.
Article 1 Paragraph 4 states that ART ‘‘must not be applied
for the purposes of sex selection (sexing) or to affect any
other biological trait of a future child with the exception of
cases involving gender-related disease prevention’’. Article
6, which refers to the diagnosis and treatment of embryos,
notes that ART may be used to prevent or treat hereditary
or genetic diseases ‘‘with sufficient certainty of a positive
diagnosis and therapeutic outcome and with the informed
consent of the couple’’. Paragraph 1 states that in vitro in-
tervention on embryos conducted for diagnosis purposes
may only be carried out to evaluate its viability or to detect
hereditary diseases.With respect to in vitro interventions on
embryos for therapeutic purposes, Paragraph 2 states that
‘‘it must have no other purpose other than to treat a disease
or prevent its transmission, and it must be conducted based
on a firm guarantee of success’’.
In 2012, new bills reflected consensus agreements
reached between professional societies in this area of
legislation. Of note is Bill 4892/2012, which established the
Assisted Reproduction Statute and which is still awaiting
consideration by the Plenary. Specific reference to PGD in
Chapter I, Article 4, largely reproduces guidelines presented
in Resolution CFM 1957/10. Article 5 adds that ‘‘medical
techniques of reproductive treatment may also be applied to
prevent the transmission of diseases that are considered
dangerous to the child’’.
On May 9, 2013, resolution CFM 2.013 was published
after insistent and recurrent requests from fertility clinics
throughout the country to provide protocols for cases in
which dilemmas with assisted reproduction occur. This
resolution revoked CFM 1957/2010 and solicited input
from regional medical councils and professional societies
across the country for a review of the previous resolution. In
accordance with the prior resolution, Article 1, Paragraph 4
confirmed that ‘‘ART should not be used for the purpose of
sex selection (presence or absence of a Y chromosome) or
to affect any other biological feature of a future child except
in cases that involve gender-related disease prevention’’.
Article 6 directly refers to PGD and establishes two pur-
poses for the technique’s application: 1) diagnosis of genetic
alterations that promote the development of diseases and
2) embryonic human leukocyte antigen (HLA) system typing
to select compatible embryos for a sibling who is already
affected by a disease. Discussion of other aspects of PGD
continues to be limited.
Discussion
Although ART availability still varies geographically,
78% of the world’s population resides in countries in which
IVF services are offered. However, in reality, many factors,
such as treatment costs, cultural and religious differences,
travel distances, and limited awareness, prevent individ-
uals from accessing this service. Ways in which access
to this service should be funded and regulated are likely
debated in all countries that provide ART. These debates
are especially complex in the case of developing countries
such as Brazil, where resources are sparse and competing
health needs are prominent. According to the analysis by
Dyer and Pennings (26) of government investment in ART
in cases of scarce State resources, resources must be
dedicated to areas that most effectively promote health
relative to diseases and disabilities that either endanger life
or significantly impair human welfare, and which may be
treated with effective interventions that substantially benefit
the individual.
Given the risks posed by hereditary genetic diseases, it
is evident that the demand for attention cannot be ignored
and that guidelines on the prevention and treatment of such
cases should be prioritized. Prevention through genetic
counseling can reach a larger number of individuals and is
less expensive (27), although PGD for couples who wish to
have children but who present specific genetic risks has
proved effective in reducing the transmission of diseases
that could seriously affect families and society as a whole
(4).
However, to perform PGD, the woman must undergo
IVF treatment, which comeswith risks, side effects, and high
costs. According to the American Society for Reproductive
Medicine, the average cost of IVF in the United States is
US$12,400 per cycle, and an additional US$3,000-5,000 is
required to execute the PGD procedure (28). This is an
important point when one considers the costs of ART to the
State and the estimation of average life costs per child for
congenital abnormalities, which could in some cases be
prevented through the use of this technique. Estimation of
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the average life cost per child for congenital abnormalities
should include, in addition to medical treatment, develop-
ment services (such as physiotherapy, speech therapy, and
occupational therapy), special or inclusive education, loss of
productivity due to disability or death, and loss of income for
the relative responsible for child care (27). These psycho-
logical and financial impacts on families with children with
congenital abnormalities or hereditary diseases are con-
siderable enough to justify investment in preventative public
policies (24).
An analysis of legislative regulation on ART in Brazil
shows that some advances have been achieved over time.
Nevertheless, ethical and technical aspects of PGD are
superficially addressed, and most of the legislation simply
reproduces the CFM resolution, providing no additional
directive on the regulation of PGD and failing to address
ethical, scientific, and legal repercussions of this selective
technique. Because such legislation is typically written
by physician parliamentarians, these documents present
several clinical arguments which promote the notion that
technical authority should prevail over beliefs and values
(14).
It is worth noting that, while PGDwas originally designed
for families that are affected by serious or fatal hereditary
genetic diseases, the method has been applied to select
features that are unrelated to diseases that seriously affect
the individual, thus raising ethical questions on a global
scale that must be considered by society, experts, and
policy makers in Brazil. Among others, examples of such
cases include the selection of embryos based on histocom-
patibility (HLA) for the donation of tissues, the diagnosis
of genetic susceptibility to disease, and fetal sex selection
without medical indications.
Concerning embryo selection for HLA, in 2012 Figueira
et al. (29) reported on the first successful birth in Brazil
through PGD for b-thalassemia combined with the selection
of an HLA-matched embryo for a sick sibling. This confirmed
the application of this practice in Brazil as defined by the
CFM resolution. However, the ethical issue that arises in the
case of HLA embryo selection concerns motivations for
conception that involve healing the eldest sibling. According
to Wolf et al. (30), in cases where a disease affects the older
sibling but has no hereditary basis, risks associated with IVF
or embryo biopsy procedures would be imposed upon the
younger child without any delivering countervailing benefit to
that child, which can be particularly troubling.
Regarding the capacity of PGD to diagnose genetic
susceptibility to disease, we were unable to find any specific
reference in the examined documents in Brazil to diseases
that begin in adulthood, such as hereditary breast cancer,
and that present high risks (as opposed to a certainty) of
developing. This technical indication criterion raises ques-
tions regarding how the possible benefits of PGD should be
measured for the future child and adult against the known
and unknown risks associated with this technology. Carrying
a genetic mutation associated with a particular disease does
not automatically cause the disease to develop. However,
in some cases, it may be possible to establish an early
prevention strategy and thus promote the discovery of a
future cure (31).
The Human Genome Project and other initiatives in this
area have promoted a new understanding of genetic
diseases, which has been constantly changing. According
to this new concept, virtually all diseases result from the
combined influence of genes and one’s environment; how-
ever, the effect of the genetic component can range from
minor to significant. The ability to test genetic sequences
associated with diseases and other hereditary character-
istics is growing more sophisticated, and, according to the
National Center for Biotechnology Information, genetic test-
ing for more than 1,000 genetic diseases is either currently
available or in development (4).
Hence, the legitimacy of medical practices with respect
to genetic determinism should be considered of particular
importance. The indication that PGD can be applied to
prevent genetic disease, as noted in Resolution CFM 2013/
2013 and several bills that are currently being analyzed by
the Congress, does not define inclusion criteria on the
technique’s use. The use of terms such as ‘‘disease-causing
genetic alteration’’ and ‘‘serious hereditary diseases’’
enables a fairly broad interpretation of this criterion.
With respect to the use of PGD for sex selection, since
the first ethical standard in the CFM (CFM 1358/1992)
was established in Brazil, it was clearly opposed to sex
selection for preventing diseases linked to sex. A recent
study assessed the perceptions of 723 Brazilian obste-
trician-gynecologists on different aspects of PGD (32), and
disagreement among the physicians was evident with
respect to CFM resolutions: 36.4% believed that selection
should always consider parental preferences, 42.6%
believed that parental preferences should be considered
only in specific cases, and only 17.4% disagreed with the
couple’s participation in sex selection.
The use of PGD for sex selection with no medical
grounds has raised ethical concerns on whether this may
promote sexual discrimination. According to those opposed
to the use of PGD for this purpose, sex selection reflects the
couple’s child preference, and this may cause future
frustration in family relationships if the child does not meet
expectations imposed by his or her gender stereotype (33).
For others, in cases where parents have an explicit pref-
erence for a certain sex, it is possible that the child and
couple will benefit if gender expectations are fulfilled. How-
ever, it has been highlighted that, in cultures where there
is an explicit preference for boys, such as China and
India, sexual selection will reinforce existing gender roles,
encouraging stereotypical behaviors such as the devalua-
tion of women (34).
In most countries, there is no clear explanation for the
choice of criteria adopted to validate different values and
guiding principles on PGD regulation. Nevertheless, there
is a strong correlation between the existence of moral and
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legal statutes on the embryo and the use of restrictive
regulations on PGD (2). There are two major approaches
to the moral and legal status of the embryo. In the first
approach, the embryo is considered a human life with
rights to full moral status from the moment of conception,
because from conception onward a complete person may
develop. This policy was adopted in Austria and Italy,
where PGD is prohibited and where the embryo is entitled
to complete protection under law. In the second approach,
the embryo assumes the right to moral status from the
moment of fertilization, but to a lesser degree than a person
who has been born (‘‘gradualist’’ statute) (4,34). In such
cases, PGD is typically permitted for medical purposes.
Countries that follow this policy include the United
Kingdom, Canada, France, and India (2).
Perceptions among experts on this topic in Brazil are
partly elucidated in a study by Caldas et al. (32). When
asked about the potential for human life to develop from a
pre-embryo of six to eight cells, 23.5% did not respond to
the question, demonstrating a moderate level of doubt on
the issue, whereas 61.1% reported that the pre-embryo
holds full potential for the development of human life. Given
the presence of diverging opinions and cultural nuances
within the population, discussions on the regulation of
reproductive genetics technologies such as PGD will be
crucial to depolarizing this debate and to knowing what
Brazilians really think about this.
Final considerations
Despite recent advances in ART regulation in Brazil, no
specific legislation on assisted reproduction and PGD
currently exists. Limited data on the practice of PGD in
Brazil suggest inequality in terms of access, where a
vulnerable proportion of the population that depends on the
public health system remains excluded. These inequalities
are exacerbated by a lack of specific regulation based on
SUS principles and international agreements on individual
reproductive rights.
In an environment where public services are not the
focus of government investment and where there is limited
ART regulation, several challenges emerge. Resolution
CFM 2.013/13, the main official document that stand-
ardizes ethical conduct on ART in Brazil, represents an
initial step toward PGD regulation, and limited discussion
on ethical scientific dilemmas stemming from this selective
technique continues. Thus, the safety and reliability of
this method depend on individual experts, and decisions
on ethical issues are often made by clinicians based on
personal judgments of what is legal and ethical.
PGD regulation in Brazil thus not only requires a broad
discussion on governing consensus in the legislature, but
public policies, practices, and regulations must also be
considered as part of the national political and economic
context, given the presence of social inequalities that restrict
rights and preclude the exercise of citizenship.
More data on this issue are needed, as there is
insufficient information available to help patients, experts,
and public policy professionals understand the current state
of the practice of PGD in Brazil. Thus, in the future, we
propose the standardization of access to PGD, based on
specific criteria whereby a consensus on principles guides
regulations that integrate scientific, ethical, and public policy
concerns in Brazil.
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